← Leaderboards
Lena Serghides
University Health Network
$1,443,222
Attributed
$1,443,222
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $353.3K · FY2020–24$500K$375K$250K$125K$0
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$1,443,222 · 1
By mechanism
R01$1,443,222 · 1
Top collaborators
No co-investigators on record.
Most similar at University Health Network
Same institution · by research overlap
- Kristy Brock$5,338,325
- Lillian L Siu$7,112,131
- Harry Janssen$5,601,644
- Amit M Oza$5,891,072
- David R Grant$1,428,444
Others in their field
Other Emerging Leaders on “Exposure To”
- Chanza Baytop · Westat, Inc.$271,217,917
- Yunda Huang · Fred Hutchinson Cancer Center$65,418,952
- Prasant Mohapatra · University Of California At Davis$51,108,355
- Ellen Gould Chadwick · Harvard University D/B/A Harvard School Of Public Health$25,473,113
- Leonard Freedman · Leidos Biomedical Research, Inc.$20,851,347
- Kristin Aillon · Midwest Research Institute$18,958,174
Research focus
Exposure ToAnti-Retroviral AgentsExperimental StudyAnimalsBiomarker SelectionBlood Glucose RegulationBotswanaAnimal DataCarbonClinically RelevantClinically SignificantComplementConceptionsCongenital AbnormalityCongenital AnomalyContractsDefectAntiretroviral TherapyDoseEfavirenzEmbryoEmbryo CultureEnvironmentFetal
Grant awards (5)
Defining the impact of dolutegravir on the maternal metabolic environment and its implications on risk of congenital anomalies.$226,760
R01 · FY2024 · HD · contact PI
Defining the impact of dolutegravir on the maternal metabolic environment and its implications on risk of congenital anomalies.$263,042
R01 · FY2023 · HD · contact PI
Defining the impact of dolutegravir on the maternal metabolic environment and its implications on risk of congenital anomalies.$321,745
R01 · FY2022 · HD · contact PI
Defining the impact of dolutegravir on the maternal metabolic environment and its implications on risk of congenital anomalies.$353,285
R01 · FY2021 · HD · contact PI
Defining the impact of dolutegravir on the maternal metabolic environment and its implications on risk of congenital anomalies.$278,390
R01 · FY2020 · HD · contact PI